Literature DB >> 11517155

A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ER alpha.

F Larrea1, R García-Becerra, A E Lemus, G A García, G Pérez-Palacios, K J Jackson, K M Coleman, R Dace, C L Smith, A J Cooney.   

Abstract

It has previously been demonstrated that 19-nor contraceptive progestins undergo in vivo and in vitro enzyme-mediated A-ring double bond hydrogenation. Bioconversion of 19-nor progestins to their corresponding tetrahydro derivatives results in the loss of progestational activity and acquisition of estrogenic activities and binding to the ER. Herein, we report subtype-selective differences in ligand binding and transcriptional potency of nonphenolic synthetic 19-nor derivatives between ER alpha and ER beta. In this study, we have examined both ER- and PR-mediated transcriptional activity of a number of A-ring chemically reduced derivatives of norethisterone and Gestodene. Double bond hydrogenation decreased the transcriptional potency of norethisterone and Gestodene through both PR isoforms with a 100- to 1,000-fold difference, respectively. In terms of the effects of norethisterone and Gestodene and their corresponding 5 alpha-dihydro (5 alpha-norethisterone and 5 alpha-Gestodene), or 3 alpha,5 alpha-tetrahydro or 3 beta,5 alpha-tetrahydro derivatives (3 alpha,5 alpha-norethisterone/3 alpha,5 alpha-Gestodene and 3 beta,5 alpha-norethisterone/3beta,5 alpha-Gestodene, respectively) on estrogen-mediated transcriptional regulation, the 3 beta,5 alpha-tetrahydro derivatives of both norethisterone and Gestodene showed the highest induction when HeLa cells were transiently transfected with an expression vector for ER alpha. This activity could be inhibited with tamoxifen. These compounds did not activate gene transcription via ER beta, and none of them showed antagonistic activities through either ER subtype. The 3 beta,5 alpha-tetrahydro derivatives of both norethisterone and Gestodene were active in other cells in addition to HeLa cells and activated reporter expression through the oxytocin promoter. In summary, two ER alpha selective agonists have been identified. These compounds, with ER alpha vs. ER beta selective agonist activity, may be useful in evaluating the distinct role of these receptors as well as in providing useful insights into ER action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517155     DOI: 10.1210/endo.142.9.8401

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Comparing the androgenic and estrogenic properties of progestins used in contraception and hormone therapy.

Authors:  Renate Louw-du Toit; Meghan S Perkins; Janet P Hapgood; Donita Africander
Journal:  Biochem Biophys Res Commun       Date:  2017-07-12       Impact factor: 3.575

Review 2.  Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Authors:  Frank Z Stanczyk; Janet P Hapgood; Sharon Winer; Daniel R Mishell
Journal:  Endocr Rev       Date:  2012-12-13       Impact factor: 19.871

3.  Transactivation of progestin- and estrogen-responsive promoters by 19-nor progestins in African Green Monkey Kidney CV1 cells.

Authors:  A M Pasapera; R Gutiérrez-Sagal; R García-Becerra; A Ulloa-Aguirre; J F Savouret
Journal:  Endocrine       Date:  2001-12       Impact factor: 3.633

4.  Both estrogen receptor α and β stimulate pituitary GH gene expression.

Authors:  Dimiter Avtanski; Horacio J Novaira; Sheng Wu; Christopher J Romero; Rhonda Kineman; Raul M Luque; Fredric Wondisford; Sally Radovick
Journal:  Mol Endocrinol       Date:  2013-01-01

5.  Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor alpha selective activity.

Authors:  Hai-Bing Zhou; Kathryn E Carlson; Fabio Stossi; Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  Bioorg Med Chem Lett       Date:  2008-11-06       Impact factor: 2.823

6.  Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase.

Authors:  Barbara J Attardi; Trung C Pham; Lisa C Radler; Janet Burgenson; Sheri A Hild; Jerry R Reel
Journal:  J Steroid Biochem Mol Biol       Date:  2008-06       Impact factor: 4.292

Review 7.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

8.  Screening estrogenic activities of chemicals or mixtures in vivo using transgenic (cyp19a1b-GFP) zebrafish embryos.

Authors:  François Brion; Yann Le Page; Benjamin Piccini; Olivier Cardoso; Sok-Keng Tong; Bon-chu Chung; Olivier Kah
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

9.  Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure.

Authors:  Fernando M Reis; Larissa M Coutinho; Silvia Vannuccini; Frédéric Batteux; Charles Chapron; Felice Petraglia
Journal:  Hum Reprod Update       Date:  2020-06-18       Impact factor: 15.610

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.